向HMGCS1恢复了急性髓性白血病的化疗敏感性
Cheng Zhou1,2, Jue Li2, Xiaofan Sun1
1Department of Hematology, The First Affiliated Hospital of Jinan University, Guangzhou, Guangdong 510630, China.
Blood science (Baltimore, Md.)
|July 12, 2024
概括
向3 - 基-3 - 甲基谷合酶A合成酶1 (HMGCS1) 显示出治疗复发性和耐火性急性髓性白血病 (AML) 的前景. 抑制HMGCS1可以减少癌细胞的生长,并提高化疗的有效性.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 生物化学 生物化学
背景情况:
- 急性髓性白血病 (AML) 的预后不好,特别是在复发和耐火病例中.
- 新的治疗目标对于改善RRAML患者的治疗结果至关重要.
研究的目的:
- 调查3 - 基-3 - 甲基氨基基共酶A合成酶1 (HMGCS1) 在AML中的作用和机制.
- 评估HMGCS1作为RRAML的潜在治疗点.
主要方法:
- 临床标本和AML动物模型的分析.
- 在体外研究涉及AML细胞系和原发性骨髓细胞.
- 基因淘汰/过度表达实验和通路分析 (MAPK).
- 用HMGCS1抑制剂 (hymeglusin) 和化疗剂 (cytarabine,ADR) 的治疗.
主要成果:
- 在RR AML中,HMGCS1过度表达,与总生存率降低相关.
- HMGCS1敲除降低了AML细胞增殖和增加了化疗敏感性.
- HMGCS1通过MAPK路径促进AML.
- 希米格卢辛抑制了AML细胞生长,并与标准化疗显示出协同效应.
结论:
- HMGCS1在AML的进展中发挥着重要作用.
- 针对HMGCS1使用像红红素这样的抑制剂是治疗RRAML的一个有希望的策略.
相关概念视频
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K


